Envestnet Asset Management Inc. Cuts Stock Holdings in Lantheus Holdings, Inc. $LNTH

Envestnet Asset Management Inc. reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 36.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,231 shares of the medical equipment provider’s stock after selling 53,351 shares during the period. Envestnet Asset Management Inc. owned approximately 0.14% of Lantheus worth $4,833,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of LNTH. Hantz Financial Services Inc. boosted its stake in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the period. Ashton Thomas Private Wealth LLC raised its holdings in Lantheus by 68.1% in the third quarter. Ashton Thomas Private Wealth LLC now owns 21,312 shares of the medical equipment provider’s stock valued at $1,093,000 after acquiring an additional 8,632 shares in the last quarter. United Community Bank lifted its stake in Lantheus by 15.6% in the third quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 245 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Lantheus by 5.5% in the third quarter. Principal Financial Group Inc. now owns 206,472 shares of the medical equipment provider’s stock worth $10,590,000 after acquiring an additional 10,722 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in Lantheus by 2.4% during the 3rd quarter. Arizona State Retirement System now owns 20,450 shares of the medical equipment provider’s stock worth $1,049,000 after acquiring an additional 487 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Mizuho lifted their price objective on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Truist Financial lifted their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Up 0.9%

LNTH opened at $73.87 on Monday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The business has a 50 day moving average price of $67.24 and a two-hundred day moving average price of $59.55. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a market cap of $4.90 billion, a PE ratio of 31.04 and a beta of -0.08.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.